<DOC>
	<DOCNO>NCT02316821</DOCNO>
	<brief_summary>The purpose study assess safety efficacy RTA 402 chronic kidney disease ( CKD ) patient type 2 diabetes double-blind , placebo-controlled study compound administer daily 16 week intrapatient dose escalation design .</brief_summary>
	<brief_title>The Phase II Study Bardoxolone Methyl Patients With Chronic Kidney Disease Type 2 Diabetes ; TSUBAKI Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>CKD patient type 2 diabetes mellitus Patients whose estimate GFR level eligible study Patients treat stable dose angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin II receptor blocker ( ARB ) etc . Patients type 1 diabetes mellitus Patients know nondiabetic renal disease Patients history renal transplantation Patients mean systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 90 mmHg Patients Hemoglobin A1c &gt; 10 % Patients cardiovascular disease specify study protocol etc .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetic Nephropathies</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
	<keyword>Diabetes Complications</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>bardoxolone methyl</keyword>
</DOC>